Defining, identifying and addressing problematic polypharmacy within multimorbidity in primary care: a scoping review

Jung Yin Tsang,Matthew Sperrin,Thomas Blakeman,Rupert A Payne,Darren Ashcroft

DOI: https://doi.org/10.1136/bmjopen-2023-081698

IF: 3.006

2024-05-25

BMJ Open

Abstract:Introduction Polypharmacy and multimorbidity pose escalating challenges. Despite numerous attempts, interventions have yet to show consistent improvements in health outcomes. A key factor may be varied approaches to targeting patients for intervention. Objectives To explore how patients are targeted for intervention by examining the literature with respect to: understanding how polypharmacy is defined; identifying problematic polypharmacy in practice; and addressing problematic polypharmacy through interventions. Design We performed a scoping review as defined by the Joanna Briggs Institute. Setting The focus was on primary care settings. Data sources Medline, Embase, Cumulative Index to Nursing and Allied Health Literature and Cochrane along with ClinicalTrials.gov, Science.gov and WorldCat.org were searched from January 2004 to February 2024. Eligibility criteria We included all articles that had a focus on problematic polypharmacy in multimorbidity and primary care, incorporating multiple types of evidence, such as reviews, quantitative trials, qualitative studies and policy documents. Articles focussing on a single index disease or not written in English were excluded. Extraction and analysis We performed a narrative synthesis, comparing themes and findings across the collective evidence to draw contextualised insights and conclusions. Results In total, 157 articles were included. Case-finding methods often rely on basic medication counts (often five or more) without considering medical history or whether individual medications are clinically appropriate. Other approaches highlight specific drug indicators and interactions as potentially inappropriate prescribing, failing to capture a proportion of patients not fitting criteria. Different potentially inappropriate prescribing criteria also show significant inconsistencies in determining the appropriateness of medications, often neglecting to consider multimorbidity and underprescribing. This may hinder the identification of the precise population requiring intervention. Conclusions Improved strategies are needed to target patients with polypharmacy, which should consider patient perspectives, individual factors and clinical appropriateness. The development of a cross-cutting measure of problematic polypharmacy that consistently incorporates adjustment for multimorbidity may be a valuable next step to address frequent confounding.

medicine, general & internal

What problem does this paper attempt to address?

This paper aims to explore the issue of how to intervene in patients with polypharmacy in the context of multiple comorbidities. Specifically, the objectives of the paper include:

1. **Understanding the definition of polypharmacy**: The paper first explores different ways of defining polypharmacy, including quantitative definitions (based on the number of drugs) and qualitative definitions (based on the quality of drug use). These definitions are crucial for identifying which patients need intervention.

2. **Identifying problematic polypharmacy in practice**: The paper analyzes methods for identifying problematic polypharmacy in practice. This includes using simple drug - quantity thresholds, screening methods for high - risk groups, and tools and techniques for assessing the appropriateness of individual drugs.

3. **Solving polypharmacy problems through intervention measures**: Finally, the paper explores existing intervention measures that aim to reduce adverse drug reactions, improve the appropriateness of drug use, reduce falls, improve patient compliance, and maintain quality of life, etc. The paper also pays special attention to intervention measures for deprescribing and points out that there are fewer intervention measures for underprescribing.

Overall, the main problem that the paper attempts to solve is that current intervention measures for patients with polypharmacy are insufficient, especially lacking consistency and comprehensiveness in terms of definition, identification, and intervention. Through a systematic review of the literature, the paper hopes to provide guidance for future research and practice to manage polypharmacy problems more effectively.